Avalo Therapeutics (AVTX) Set to Release Earnings on Thursday

Key Points

• Avalo Therapeutics is expected to report Q3 2026 results before the market opens on Thursday, November 5. Analysts anticipate a loss of $0.5946 per share; the earnings call is scheduled for November 9 at 9:30 a.m. ET.
• The company previously reported a third-quarter loss of $0.83 per share, missing the $0.58 consensus estimate. Analysts project full-year and next-year losses of $2.95 and $2.62 per share, respectively.
• AVTX shares opened at $7.12, near their 12-month low of $6.53, while analyst sentiment remains a “Moderate Buy” with a $37 consensus price target. Recent ratings were mixed, including target-price cuts and a downgrade to neutral.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.5946) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, analysts expect Avalo Therapeutics to post ($2.95) EPS for the current fiscal year and ($2.62) EPS for the next fiscal year.

Avalo Therapeutics Trading Up 5.5%

Shares of AVTX stock opened at $7.12 on Thursday. The firm has a market capitalization of $381.85 million, a PE ratio of -1.63 and a beta of 0.68. The firm has a fifty day simple moving average of $15.29 and a two-hundred day simple moving average of $16.16. Avalo Therapeutics has a 12 month low of $6.53 and a 12 month high of $24.27.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on AVTX shares. BTIG Research dropped their price objective on shares of Avalo Therapeutics to $10.00 and set a "buy" rating on the stock in a research note on Friday, October 23rd. Weiss Ratings raised shares of Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wedbush decreased their target price on shares of Avalo Therapeutics from $34.00 to $22.00 and set an "outperform" rating for the company in a research report on Friday, October 23rd. Guggenheim lowered shares of Avalo Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, October 23rd. Finally, Leerink Partners began coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an "outperform" rating and a $38.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Avalo Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $37.00.

Insider Transactions at Avalo Therapeutics

In related news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the sale, the chief financial officer directly owned 39,900 shares of the company's stock, valued at approximately $651,567. This represents a 23.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 23,258 shares of company stock worth $395,434 in the last ninety days. Corporate insiders own 4.46% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company's research and development programs are intended to address conditions with significant unmet medical needs.

Avalo's lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.